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Abstract
Background: Copper export protein ATP7A is important for maintaining copper homeostasis. Recent studies have
shown that copper transporters are also involved in the transport of platinum. The goal of this study was to
determine the role of ATP7A in the platinum-resistance of non-small cell lung cancer (NSCLC).
Methods: Sensitivities to platinums were detected by MTT assay and drug-resistance related genes were analyzed
by real-time PCR and immunoblotting between DDP-sensitive A549 and the corresponding DDP-resistant cell
subline (A549/DDP). ATP7A expression was evaluated by immunohistochemistry in tumor tissues of unresectable
NSCLC patients who received cisplatin-basing chemotherapy.
Results: The expression of ATP7A was significantly higher in A549/DDP cell subline than in A549 cells at both
mRNA and protein levels. The silencing of ATP7A expression in A549/DDP by siRNA partially reversed DDP-
resistance (29.62%) and increased cell apoptosis. ATP7A expression was detected in 41.6%of NSCLC patients, but
not in adjacent stroma nor normal lung tissues. ATP7A-positive patients had a significantly poorer histological
grade (p = 0.039) and poorer response to platinum-basing chemotherapy (p = 0.001) compared with ATP7A-
negative patients. Cox’s proportional hazards analysis showed that ATP7A expression was an independent
prognostic factor for overall survival (p = 0.045).
Conclusions: ATP7A overexpression played an important role in platinum-resistance of NSCLC, and was a negative
prognostic factor of NSCLC patients treated with platinum-based chemotherapy.
Background
Non-small cell lung cancer(NSCLC) accounts for 80% of
all lung cancers and is a leading cause of cancer-related
death during the last decades. Platinum-based che-
motherapy is the major treatment for advanced NSCLC.
However, the best overall response rate is only 30-50%
[1]. The intrinsic/acquired resistance of tumor to plati-
num derivates limit the effectiveness of therapy [2].
Consequently, there is great need for elucidating the
mechanism of resistance to platinum in NSCLC.
There are a viariety of factors contributing to plati-
num-resistance, including decreased drug accumulation,
enhanced detoxification, and increased DNA repair effi-
ciency [3]. Although multidrug resistance-associated
protein 2 (MRP2/ABCC2) has been reported to trans-
port DDP and confered resistance to DDP [4], actually
the mechanisms of decreasing of DDP accumulation in
resistant cancer cells have not been fully elucidated yet.
One of the mechanisms might be the vesicular transport
depending on copper transporters.
Copper uptake protein CTR1, copper export proteins
ATP7A and ATP7B are important for maintaining copper
homeostasis. Recent studies have shown that copper trans-
porters are also involved in the transport of platinum.
DDP-resistant cells showed cross-resistant to copper, and
vice versa [5]. Evidences also suggested that some copper
influx transporters especially CTR1 were involved in the
cellular uptake of DDP, CBDCA and L-OHP, and the
* Correspondence: xurh@sysucc.org.cn
† Contributed equally
1State Key Laboratory of Oncology in South China, Sun Yat-Sen University
Cancer Center, Guangzhou 510060, China
Full list of author information is available at the end of the article
Li et al. Journal of Translational Medicine 2012, 10:21
http://www.translational-medicine.com/content/10/1/21
© 2012 Li et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.other two copper transporters ATP7A and ATP7B import
copper to golgi apparatus which regulates the efflux of
DDP [6]. As a P-type ATPase copper transporter, ATP7A
is expressed in many tissues except for liver and sustains
not only copper-dependent tyrosinase in melanosomes [7]
but also dopamine beta monooxygenase, lysl oxidase and
copper containing protein. ATP7B has been reported to
relate to DDP-resistance first [8,9]. Then, another copper
transporter ATP7A has also been implicated in platinum-
resistance later [10,11].
Nevertheless, it is generally accepted that platinum-
resistance most likely has multiple mechanisms and the
mechanisms of resistance may differ depending on the
cell types [12]. Whether NSCLC shares common drug
resistance mechanisms with other cancers or possesses
its own distinct characteristics is still unclear. Hence, a
better understanding of the active mechanism of plati-
num-resistance in NSCLC may lead to new treatment
strategies and allow selection of patients for specific
treatment modalities.
Methods
Drugs
DDP and CBDCA were purchased from Bristol-Myers
Squibb (NY, USA), and L-OHP was provided by Sanofi-
aventis (Paris, France). DDP and CBDCA were diluted
and stored according to the method described [13].
L-OHP was diluted in water stored as a 12.6 mM stock
solution at -20°C.
Cell Lines and Cell Culture
Human NSCLC cell lines included the parental cell line
A549 and the cell subline A549/DDP which was resis-
tant to DDP. All the cells were generously provided by
State Key Laboratory of Oncology in Southern China
and were all cultured according to the method described
[13]. Cells used for the experiments were in the loga-
rithmic phase of growth.
MTT Assay
The cytotoxicities of DDP, CBDCA and L-OHP were
determined by MTT assay according to the method
described [14]. The dose-response curve could be
plotted with 50% inhibitory concentration (IC50). Resis-
tance index (RI) was calculated as IC50 resistant/IC50
sensitive cell line.
Real-time PCR
The mRNA expressions of ATP7A in A549 and A549/
DDP cells were determined using real-time PCR accord-
i n gt ot h em e t h o dd e s c r i b e d[ 1 5 ] .B r i e f l y ,t o t a lR N A
from cultured cells was extracted by using the Trizol
reagent (Invitrogen) according to the manufacturer
described, and cDNAs were amplified and quantified in
ABI Prism 7500 Sequence Detection System (Applied
Biosystems) by using dye SYBR Green I (Invitrogen).
The sequence was as following: ATP7A, forword: 5’-
GCCTGCGTACGTGGATTTAT-3’ and reverse: 5’-
TCAATGGTCCAAACACAGGA-3’.G A P D Hw a su s e d
as an internal control (forward: 5’-ACCA-CAGTC-
CATGCCATCAC-3’ and reverse: 5’-TCCACCAC-
CCTGTTGCTGTA -3’).
Immunoblotting
The protein expressions of ATP7A and GAPDH were
determined using immunoblotting according to the
method described [14]. Primary antibodies were diluted
in a blocking solution 1: 500 for ATP7A (Abcam, Cam-
brige, UK) and 1:5000 for GAPDH (Boster, Wuhan,
China).
siRNA Transfection
ATP7A siRNA sequences were targeted exon 11 (sense,
GCAACUAUUGUAACUCUUG dTdT; antisense, CAA-
GAGUUACAAUAGUUGC dTdT) [16]. A nonsilencing
siRNA sequence, shown by BLAST search which did
not share sequence homology with any known human
mRNA was used as control for ATP7A-targeting experi-
ments. The siRNA sequences were synthesized by
Guangzhou RiboBio (Ghuangzhou, China). The transfec-
tion of siRNA was performed using lipofectamine-2000
(Invitrogen, CA, USA) according to the manufacturer’s
recommendation. Oligofectamine/siRNA complexes
were formed in serum free DMEM by adding siRNA
(25, 50 or 100 nM final concentration) to 5 μl of Oligo-
fectamine (Invitrogen, CA, USA) per well. Complexes
w e r ea l l o w e dt of o r ma t2 5 ° Cf o r1 0m i na n da d d e dt o
wells (500 μl per well). After 4 hours of transfection, the
culture medium containing 10% serum was added. The
assays were carried out 24, 48, 72 and 80 hours post
transfection.
Intracellular accumulation of DDP
For the characterization of DDP uptaking, 1 × 10
6 cells
were seeded in 100 mm tissue culture dishes and trans-
fected with siRNA_ATP7A and siRNA_Control by lipofa-
tamine 2000, 36 hrs later exposed to 60 μMf r e s h l y
prepared DDP. After 12 hrs of exposure to the drugs, the
media was discarded quickly and the cells were washed
three times with 5 ml ice-cold PBS buffer. Then cells
were trypsinized, scraped and resuspended in fresh drug-
free medium and centrifuged at 1,000 rpm for 5 mins.
The supernatant was discarded and the pellet was washed
twice in 1 ml ice-cold PBS buffer. After centrifugation for
2 mins at 4°C and 6,000 × g the supernatant was dis-
carded again and the cell pellet was frozen at -20°C until
analysis. Immediately after thawing, the cells were lysed
with concentrated nitric acid for 20 mins in the water
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ml of distilled water and intracellular platinum (Pt) con-
centrations were measured by the atomic spectrometer
(Varian AA Duo, USA). Pt levels were expressed as μM/1
× 106 cells, with the cell number determined by counting
(Nexcelom Cellometer Auto T4 cell counter, USA) in
parallel cultures. Experiments were performed in dupli-
cate and the values expressed were the means ± SD of
the three independent experiments.
Flow Cytometry
Apoptotic or necrotic cell death was determined by flow
cytometric analysis of cells double stained with Annexin
V-FITC and propidium iodide (PI) using an assay kit
from KeyGen Biotech (Nanjing, China). A549/DDP cells
were plated into 6-well plates and adhered for overnight.
Then 100 nM final concentration of siRNA (targeted-
ATP7A or nonsilencing siRNA) was added to wells for
transfection. After 80 hours of transfection including 72
hrs for DDP incubation, cells were collected, washed
with cold PBS, and suspended in binding buffer. The
cells were stained with Annexin V-FITC and PI for
15 minutes at room temperature in the dark. The sam-
ples were analyzed with a flow cytometry (BECKMAN-
COULTER FC500, CA, USA).
Patients and Samples
Between October 2006 and August 2008, the medical
records of pathology-proven unresectable (local
advanced or distant metastasis) non-small cell lung can-
cer patients who were diagnosed and received cisplatin-
based chemotherapy in the Cancer Center of Sun Yat-
Sen University were retrospectively analyzed. We
excluded patients who had a history of other primary
cancers. Patients who were considered for the final ana-
lysis should have a performance status (PS) of grade 0
or 1 and didn’t undergo surgery or radiotherapy, but
was primarily treated with first-line cisplatin-based che-
motherapy. We totally identified 89 formalin-fixed par-
affin-embedded samples, corresponding to pretreatment
bronchoscopic or fine-needle aspiration biopsies. Diag-
nosis was based on conventional morphological exami-
nation of the sections stained with H&E staining, and
staging of tumors were classified according to the UICC
classification. The cisplatin-based regimen included cis-
platin (75-80 mg/m
2), paclitaxel (175-225 mg/m
2), or
gemcitabine (800-1000 mg/m
2, d1, d8) or navelbine (25-
40 mg/m
2 d1, d8). All of the cases received 1-6 courses
cisplatin containing regimens. Response to cisplatin-
based chemotherapy was evaluated by physicians
according to Response Evaluation Criteria in Solid
Tumors (RECIST) criteria. The follow-up for all of the
patients was updated in June 1, 2009 (median follow-up
time was 12.5 months; range, 1.7-32 months). As of the
last follow-up time, all patients had died of tumor pro-
gression. The study was approved by the institutional
review board of the hospital.
Immunohistochemical Staining
Immunohistochemical staining was performed according
to the guidelines of the Catalyzed Signal Amplification
System (ZSGB-BIO, Beijin, China). The slides were
incubated with a 1:200 dilution of anti-ATP7A antibody
(Abcam, Cambrige, UK). Adult normal kidney and lung
samples were taken as positive control and negative
control respectively. The slides were examined and
scored by two pathologists independently without
knowledge of clinical information of the patients. If
more than 10% of the tumor cells were stained, the
samples were considered to be ATP7A-positive carcino-
mas [17].
Statistical Analysis
Data analysis was performed using SPSS 16.0 statistical
software package (SPSS, IL, USA). Continuous variables
were analyzed using Student’s t test. As qualitative vari-
ables, the clinicopathologic characteristics of 89 patients
with NSCLC were analyzed using chi-square test. Survi-
val curves were determined using Kaplan-Meier method,
and differences in survival between subgroups were
compared with log-rank test. Multivariate prognostic
analysis was performed using Cox proportional hazards
model. All the reported P-values were two-sided. P <
0.05 was hypothesized to be significant.
Results
A549/DDP cells is resistant to platinum-derivate drugs
The drug sensitivities of A549 and A549/DDP cells to
three platinum-derivate drugs (DDP, CBDCA and L-
O H P )w e r es h o w ni nT a b l e1 .T h eI C 50 were 3.79 and
29.83 uM for DDP, 45.85 and 205.70 uM for CBDCA,
7.68 and 18.07 uM for L-OHP in A549 and A549/DDP
respectively. Compared with A549 cells, A549/DDP
showed 7.88 folds enhanced resistance to DDP, and
both exhibited cross-resistance to CBDCA and L-OHP
(4.49 and 2.35 folds respectively). RIs were the highest
for DDP and the lowest for L-OHP.
ATP7A was overexpressed in A549/DDP
The expression of ATP-binding cassette (ABC) trans-
porters in A549 and A549/DDP cell lines were examed
by real-time PCR and immunoblotting. As shown in
Figure 1a, ATP7A mRNA expression in A549/DDP was
much higher than in A549 (Figure 1a) and the protein
expression was also comfirmed by immunoblotting.
There was no significant difference in expressions of
MDR1, ABCG2, MRP1, LRP, GST-pi, DNApolb,C T R 1
and ATP7B (data not shown). These results indicated
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resistance in A549/DDP cells.
Inhibition of ATP7A expression by siRNA enhance
chemosensitivity to DDP in A549/DDP
T of u r t h e rd e t e r m i n et h er o l eo fA T P 7 Ai np l a t i n u m -
resistance of A549/DDP cells, we used RNA interference
system to knockdown the expression of ATP7A in
A549/DDP cells. As shown in Figure 2, 100 nM
ATP7A-targeted siRNA sequences, the silenced most
expression of ATP7A protein in A549/DDP cells (76.0 ±
0.08%). The reversal effect of the siRNA transfection
(100 nM, 80 hrs) on the DDP-resistance of A549/DDP
was investigated by MTT assay. As shown in Table 2,
siRNA transfection targeting ATP7A reduced IC50 of
A549/DDP cells significantly compared with controls
(reversal effects of 29.62%). Silencing ATP7A was able
to partially reverse DDP-resistance in A549/DDP cells.
These results indicated that ATP7A played an important
role in the modulation of platinum-resistance in A549/
DDP.
To further determine whether ATP7A-targeted siRNA
transfection could reverse the platinum-resistance of
A549/DDP, DDP-induced apoptosis was detected by
A n n e x i nV - P Ia s s a y .A ss h o w ni nF i g u r e3 ,w i t h o u t
DDP, there was little apoptosis and no significant differ-
ence between ATP7A-targeted siRNA group and control
siRNA group. But after treatment with different concen-
trations of DDP for 72 hrs, cell apoptotic rates in
ATP7A siRNA group were significantly higher than in
control siRNA group (28.37 ± 1.25% compared to 16.43
± 1.40% at 30 uM DDP and 48.33 ± 2.16% compared to
Table 1 Drug sensitivity of A549 and A549/DDP cells to
platinum derivatives (DDP, CBDCA and L-OHP)
aIC50 (mean ± SD, uM)
Drugs A549 A549/DDP
bRI P
DDP 3.79 ± 0.11 29.83 ± 1.25 7.88 < 0.001
CBDCA 45.85 ± 1.24 205.70 ± 3.02 4.49 < 0.001
L-OHP 7.68 ± 0.28 18.07 ± 0.39 2.35 < 0.001
Cells were precultured for 24 hrs at a density of 5*10
3 cells/well in 96-well
multiplates.Cytotoxicity was determined 72 hrs after drug exposure by MTT. a,
IC50, inhibitory concentration that kills 50% of cell population. Data represents
the mean ± SD of at least three independent experiments performed with 8
wells at each drug concentration tested. b, RI, resistance index calculated as
IC50 resistant/IC50 sensitive cell line. SD, standard deviation; DDP, cisplatin;
CBDCA, carboplatin; L-OHP, oxaliplatin. P < 0.05 was considered as a
significant change in drug sensitivity (Student’s t-test)
Figure 1 Expression of ATP7A at RNA and protein levels in
A549 and A549/DDP cells. a, total of RNA isolated from A549 and
A549/DDP cells was subjected to real-time PCR for ATP7A b, ATP7A
protein expression was determined by Western-blot analysis using
anti-ATP7A antibody. Equal loading was confirmed with GAPDH as a
control in real-time PCR and Western-Blot.
Figure 2 Effect of ATP7A-siRNA 80 h on ATP7A protein
expression in A549/DDP ells. Equal loading was confirmed with
GAPDH as a control. Western blot analysis of ATP7A in A549/DDP
cells following treatment with control siRNA and different
concentrations of targeted ATP7A siRNA (25 nM, 50 nM and 100
nM) for 80 h. Protein expression was quantified by Quantity One
software. Results are the representative of three similar experiments.
Table 2 Partially reversal effect after ATP7A’s silence by
siRNA for 80 h in the DDP-resitant subline A549/DDP
cell lines IC50 (mean ± SD,
uM)
areversal effect
(%)
P
A549/DDP 29.33 ± 0.20
A549/DDP Control
SiRNA
29.51 ± 0.17 > 0.05
A549/DDP ATP7A
SiRNA
20.77 ± 0.28 29.62 < 0.001
ATP7A siRNA group is A549/DDP cells treated with ATP7A siRNA sequences at
the final 100 nM concentration for 8 hrs and then added DDP at various
concentrations for 72 hrs. Control siRNA group is A549/DDP cells treated with
nonsilencing siRNA sequences at the final 100 nM concentration for 8 hrs and
then added DDP at various concentrations for 72 hrs. a, reversal effect was
determined by the percentage of the IC50 difference between Control siRNA
group and ATP7A siRNA group to the IC50 of Control SiRNA groups. Data
represents the mean ± SD of at least three independent experiments
performed with 8 wells at each drug concentration tested. P < 0.05 was
considered as a significant change in drug sensitivity (Student’s t-test). SD,
standard deviation; DDP, cisplatin
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by siRNA enhanced DDP-induced apoptosis significantly
compared with control siRNA at different DDP concen-
trations (P < 0.01). These results ‘further confirmed that
ATP7A played a role in modulation of platinum-resis-
tance in A549/DDP cells.
Effect of ATP7A on the intracellular accumulation and
efflux of platinum
To investigate how does ATP7A modulated platinum
resistance, cellular accumulation of DDP was examined
in A549, A549/DDP and A549/DDP cells transfected
w i t hs i R N AA T P 7 Ao rs i R N Ac o n t r o l .C e l l sw e r ei n c u -
bated in medium containing 60 μM freshly prepared
DDP for 12 hrs and the level of DDP in cell lysates was
then measured. As shown in Table 3, intracellular
amounts of DDP in A549/DDP cells transfected with
siRNA control (0.06 ± 0.005 uM/10
6 cells) were much
lower than in the parental A549 cells (0.69 ± 0.007 uM/
10
6 cells) (p < 0.001). and intracellular amounts of DDP
in A549/DDP cells transfected with siRNA ATP7A (0.13
± 0.003 uM/10
6 cells) were significantly higher than in
A549/DDP cells transfected with siRNA control (p <
0.001). These data strongly suggested that the decreased
DDP accumulation in A549/DDP cells was due to an
ATP-dependent DDP transporting activity of ATP7A,
which mediated platinum-resistance.
ATP7A expression was negatively correlated with
response to DDP-based chemotherapy in NSCLC
To investigate the expression of ATP7A in NSCLC tissue,
and analyze its correlation to the clinicopathologic features
and prognosis of NSCLC, immunohistochemistry method
Figure 3 Increasing DDP induced apoptosis after ATP7A’s silence for 80 h by siRNA in A549/DDP cells. Apoptotic or necrotic cell death
was tested by flow cytometric analysis. Control siRNA, added 100 nM nonsilencing siRNA sequences for 8 h and then added DDP for 72 h;
ATP7A siRNA, added 100 nM SiRNA targeting ATP7A for 8 h and then added DDP for 72 h. Columns, mean of three independent experiments;
bars, SD.
Table 3 Intracellular accumulation of DDP in A549 cells,
A549/DDP cells and A549/DDP cells treated with control
siRNA or ATP7A siRNA respectively
cells Concentration (μmol/10
6 cells) P
A549 0.69 ± 0.007
A549/DDP 0.06 ± 0.002 < 0.001
A549/DDP_Control_siRNA 0.06 ± 0.005
A549/DDP_ATP7A_siRNA 0.13 ± 0.003 < 0.001
Pt levels were expressed as μmol/1 × 10
6 cells (A549 cells, A549/DDP cells
and A549/DDP cells treated with control siRNA ATP7A siRNA). Experiments
were performed in duplicate and the values expressed were the means ± SD
of the three independent experiments
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detected in cytoplasmic staining of tumor cells in 37 of 89
(41.6%) tumors but not in adjacent stroma nor normal
lung tissue. Associations were sought between ATP7A
expression and the clinicopathologic characteristics of 89
patients including age, gender, stage, performance status
(PS), histological subtype, histological grade, serum Carci-
noembryonic Antigen (CEA) status, response to che-
motherapy and overall survival (OS). The clinical
parameters of the 89 patients in this study were summar-
ized in Table 4. ATP7A expression was negatively corre-
lated with response to DDP-basing chemotherapy (P =
0.001) and histological grade (P = 0.039). No significant
association was found between ATP7A expression and age
(P = 0.469), gender (P = 0.442), stage (P = 0.436), PS (P =
0.361), histological subtype (P = 0.67) and serum CEA sta-
tus (P = 0.661). The median overall survival (mOS) of all
patients was 12.53 months. In 37 patients with ATP7A
positive staining, the mOS was 11.03 months, and the
mOS was 14.02 months in 52 patients with ATP7A nega-
tive staining. As shown in Figure 5, Kaplan-Meier analysis
indicated that ATP7A positive patients had inferior survi-
val compared with ATP7A negative patients (P =0 . 0 2 1 ,
log-rank test). In univariate analysis, ATP7A, stage, PS,
serum CEA status and histological grade were significantly
correlated with survival (P = 0.021, 0.019, 0.004, 0.022 and
0.013 respectively). Cox’s proportional hazards model ana-
lysis showed that 4 independent factors significantly
related to overall survival: ATP7A (RR = 1.570, 1.010-
2.440, P = 0.045), stage (RR = 1.759, 1.256-2.464, P =
0.001), CEA status (RR = 1.828, 1.162-2.874, P = 0.009)
and histological grade (RR = 1.704, 1.205-2.408, P = 0.003).
Discussion
This article sheds new light on the potential function of
copper transporter ATP7A in NSCLC. In our study, as
expected, DDP-resistant cell subline (A549/DDP) was
much more (7.88 folds) resistant to DDP than the par-
ental cells (A549). Note that this cell line also exhibited
cross-resistance to CBDCA (4.49 folds) and L-OHP
(2.35 folds). The resistant indexes of L-OHP (2.352) was
much lower than that of DDP (7.88). That could be
caused by the chemical structure of L-OHP. L-OHP
bears a 1,2-diaminocyclohexane (DACH) ligand which is
quite different from DDP and CBDCA, conferring it a
markedly different spectrum of activity from DDP and
CBDCA [18]. A549/DDP was exposed DDP by pulse
treatment which is similar to the clinical pulse protocol
for NSCLC patients to select for the drug-resistant sub-
line. CBDCA and L-OHP were not exposed to A549/
DDP in the process of establishing the cell subline. We
Table 4 The clinicopathologic characteristics of 89
patients with NSCLC treated with platinum-based
chemotherapy only in this study
Characteristics Number of patients
Total ATP7A(-) ATP7A(+) P
Age
median 57 57 57
range 31-79 35-79 31-77 0.469
Gender
male 64 39 25
female 25 13 12 0.442
Response to chemo
PR 29 24 5
SD+PD 60 28 32 0.001
Stage
III 48 28 20
IV 41 24 17 0.436
PS
04 6 2 9 1 7
> 0 43 23 20 0.361
Histology
squamous 25 14 11
adenocarcinoma 64 39 25 0.67
Grade
low 48 28 20
moderate 27 12 15
high 14 12 2 0.039
CEA status
normal 34 18 16
elevated 55 34 21 0.661
Figure 4 Immunohistochemical staining of normal and NSCLC
human tissues for ATP7A (magnification, ×400). a, adult normal
kidney tissue as positive control; b, adult normal lung tissue as
negative Control; c, ATP7A high positive case, almost all of tumor
cells showed strong positive reaction in the cytoplasm; d, ATP7A
negative case, ATP7A expression was not detectable in the
cytoplasm.
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tance to DDP, then might at a lesser extent to CBDCA
and L-OHP.
Reduced drug accumulation has been related to ATP-
binding cassette (ABC) transporters. Overexpression of
MDR1(Pgp) was capable of pumping out a variety of
diverse chemotherapy drugs to reduce intracellular drug
concentration and multidrug resistance (MDR) [19], and A
link was identified between MDR transporter Pgp, and
MAPK signaling and invasion in human melanoma cells
[20]. In clinical, MDR1 expression in childhood ALL is an
independent adverse prognostic factor on outcome, a use-
ful biological marker of response in these patients [21].
Recently, a report found that single nucleotide polymorph-
isms of ABCC5 and ABCG1 transporter genes correlated
to irinotecan-associated gastrointestinal toxicity in colorec-
tal cancer patients [22]. But in our study, the mRNA
expression levels of MDR1, ABCG2, MRP1, LRP, GST-pi,
DNApolb, CTR1 and ATP7B were almost the same
between A549/DDP and A549 cells, suggesting that the
platinum-resistance in A549/DDP cells is independent of
ABC transporters. However, ATP7A expression in both
mRNA and protein levels significantly increased in A549/
DDP cells comparing with the parental cells respectively.
Furthermore, in A549/DDP cells, ATP7A siRNA knock-
down (76.0 ± 0.08%) was able to partially reverse DDP-
resistance (29.62%). The cytotoxicity of platinum-
compounds was thought to be determined primarily by
their DNA adducts [23], which then induced cell apoptosis
[24]. In our study, ATP7A silencing significantly increased
cells apoptosis rates in A549/DDP cells. Thus, the reduced
expression of ATP7A achieved by siRNA knockdown
resulted in enhancement of DDP-sensitivity and increased
DDP-induced apoptosis. But there should be many factors
related to the resistance to DDP in A549/DDP cells, but
not only ATP7A. So it isn’t surprising that knocking down
ATP7A exepression in A549/DDP cells only partially
reversed the resistance to DDP but not mostly.
The intracellular amounts of DDP in A549/DDP cells
was much lower than in the parental A549 cells, suggest-
ing the platinum resistance of A549/DDP is due to
decreased drug accumulation. SiRNA-knockdown
ATP7A in A549/DDP cells increased the intracellular
amounts of DDP. These results indicate that the plati-
num-resistance in A549/DDP cells is mediated by
decreasing drug accumulation of ATP7A. Overexpression
of ATP7A in A549/DDP cells might pump more plati-
num into trans-Golgi network, thus decrease cellular pla-
tinum concentration and keep them from accessing their
key cytotoxic targets in the nucleus, resulting in DDP-
resistance. Recently the copper transporters have been
demonstrated to be involved in platinum-resistance in
some cancers. Samimi G demonstrated that overexpres-
sion of ATP7A in human ovarian carcinoma cells con-
fered resistance to DDP, CBDCA and L-OHP by
sequestering platinum analogues in intracellular com-
partments and preventing their reaction with nuclear
DNA [10]. Plasencia C also reported that ATP7A overex-
pression in L-OHP resistant colorectal cancer cells [25].
Consistent with those reports, our results demonstrated
that the platinum resistance is associated with ATP7A in
lung cancer cell. To our knowledge, this is the first report
about ATP7A related to platinum-resistance in NSCLC.
In clinical, we found that 41.6% (37/89) of NSCLC
patients aberrantly expressed ATP7A. However, ATP7A
protein was not detected in tumor adjacent stroma nor
normal lung tissue. This suggested that ATP7A might
be involved in transformation of a normal differentiated
cell to a malignant tumor cell. Compared with the
ATP7A-negative patients, ATP7A-positive patients had
a inferiorly histological grade (P = 0.039), inferior
response to platinum-basing chemotherapy (P = 0.001)
and poorer OS (P =0 . 0 2 1 ) .C o x ’s proportional hazards
model analysis showed that ATP7A expression was an
independently prognostic factor of survival. Some stu-
dies in ovarian cancer showed similar results that
increased expression of ATP7A mediated resistance to
platinum derivatives in cancer cells and was associated
with poor survival in ovarian cancer patients during pla-
tinum drug-based treatments [10,11].
Figure 5 Overall survival curves of NSCLC treated with
platinum-based chemotherapy. Comparison of survival curves for
patients whose tumors stained positive for ATP7A with those
patients whose tumors were classified as negative for ATP7A
expression. Curves present the results for all patients. P value was
conducted by Log-rank test.
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Page 7 of 9Conclusions
Our results demostrated that overexpression of copper
efflux transporter ATP7A was responsible for platinum
resistance in A549/DDP cells. These results indicated
that ATP7A expression assessed by immunohistochem-
istry could be a chemo-resistant marker and a negative
prognostic factor for survival in NSCLC patients treated
with platinum-based chemotherapy, providing a basis
for a better utilization of platinum-based antitumor
agents and thereby improving the survival of NSCLC
patients.
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